All relevant data are within the manuscript and its Supporting Information files.

1. Introduction {#sec005}
===============

The Republic of Ireland (ROI), like many countries, has a long and difficult history controlling tuberculosis (TB). In the first half of the 19^th^ century, the rapid growth in the population, the poor social conditions, and the effects of the Famine of 1845--1849 resulted in a national epidemic of tuberculosis \[[@pone.0238142.ref001],[@pone.0238142.ref002]\]. This epidemic persisted for an entire century. By 1945, the mortality rate from TB was 125 cases per 100,000 population. In 1948, the State embarked upon the largest program of public hospital construction in its history \[[@pone.0238142.ref003]\]. The result was the creation of several sanitoria and over 2,000 additional hospital beds for TB care \[[@pone.0238142.ref003]\]. The establishment of a mass radiography screening program aided the identification and isolation of TB cases. This coupled with the advent of anti-tuberculosis medication and a national BCG vaccination program brought the epidemic under control by the end of the 1950s \[[@pone.0238142.ref003]\]. The incidence of TB has since declined from 230 cases per 100,00 population in 1953 to 6.6 cases per 100,000 population in 2018 \[[@pone.0238142.ref004]\].

The World Health Organisation (WHO) End TB Strategy has set the target of a 90% reduction in global TB incidence by 2035 \[[@pone.0238142.ref005]\]. It is estimated the ROI will need an annual reduction of 19% to meet this target, far greater than the current 3.1% annual reduction \[[@pone.0238142.ref006]\]. The WHO outlined the challenges for meeting this goal in low incidence countries including effective TB service planning and delivery \[[@pone.0238142.ref006]\]. A challenge for health systems is maintaining TB services and clinical expertise as the incidence of TB declines to low levels \[[@pone.0238142.ref007]\].

In the ROI there is no national TB strategy as exists in other low-incidence countries, nor is there a defined budget for TB care \[[@pone.0238142.ref008]\]. There are national clinical guidelines \[[@pone.0238142.ref009]\]. The health system in the ROI compromises of both private and public healthcare. While 43.3% of the population in Ireland have private health insurance, only 14% of all healthcare expenditure is funded from private health insurance \[[@pone.0238142.ref010],[@pone.0238142.ref011]\]. In the public health service, outpatient consultations are provided at no charge to patients. Funding for TB medications are provided by the public health service, except for a €2.00 prescription charge \[[@pone.0238142.ref012]\]. Primary care is provided by 2,954 general practitioners (GP) \[[@pone.0238142.ref013]\]. An appointment with a GP is free for patients entitled to it based on a means assessment \[[@pone.0238142.ref012]\]. There is a fee to attend the emergency department without referral by a GP \[[@pone.0238142.ref014]\]. In this system, patients with symptoms of TB can present to their general practitioner or the emergency department. Patients presenting to their general practitioner with symptoms of TB can, if deemed necessary by the GP, be referred to the emergency department or an appropriate outpatient clinic depending on their clinical presentation. If a diagnosis of TB is established by a physician, they are legally obliged to notify it as a case to their local director of public health \[[@pone.0238142.ref015]\]. They can also, but are not obliged to, refer the patient to a physician in an outpatient service who has expertise in the management of TB cases. The role of the public health departments in the ROI comprises maintaining TB surveillance and performing contact tracing of notified cases where necessary. They also oversee directly observed therapy for TB patients. There are many routes through which a patient can be diagnosed with TB in the ROI which will include one or a combination of general practitioners, public health doctors and nurses, hospital outpatient and inpatient services, emergency departments and the private healthcare system.

The last reform of TB services in Ireland was outlined in a 2003 report \[[@pone.0238142.ref016]\]. It was recommended that most TB care should be delivered on an outpatient basis in acute general hospitals with a small number of beds allocated in three hospitals for inpatient TB management. This resulted in three hospitals being designated as TB centres. Consultant staffing with a special interest in TB in all three hospitals was recommended. One of these, St. James's hospital, was designated a supra-regional TB centre with co-location of the national tuberculosis reference laboratory. These hospitals were to be allocated resources to provide adequate recreation and rehabilitation facilities to serve patients with TB, including those in other non-TB centres. The national TB guidelines in Ireland state that a minority of tuberculosis patients should require hospital admission \[[@pone.0238142.ref009]\]. The guidelines also advise treatment of TB should be directed by a respiratory/infectious diseases physician with training in the management of TB \[[@pone.0238142.ref009]\].

Achieving WHO End TB targets and eliminating TB from the ROI will require purposeful action by the state in the same vein as bringing the epidemic under control did. Evaluating healthcare resource utilisation by patients admitted to hospital with TB may provide insight into how services could be improved. We aimed to describe the utilization of hospital inpatient care by patients with TB in the ROI.

2. Methods {#sec006}
==========

2.1 Data sources {#sec007}
----------------

All patients who have an episode of care in a public hospital in the ROI have their diagnostic data collected and coded according to the International Classification of Diseases-10-Australian Modification (ICD-10-AM) 8^th^ edition using a computerised system known as the Hospital Inpatient Enquiry (HIPE) system \[[@pone.0238142.ref017]\]. It is the principal source of demographic, administrative and clinical data on all episodes of care in publicly funded hospitals in the ROI. An episode of care is defined as beginning when the patient is admitted to the hospital and ends when the patient is discharged or dies \[[@pone.0238142.ref018]\].

The National Quality Assurance and Improvement System (NQAIS) Clinical is an online interactive application that analyses HIPE data to provide detailed information to clinicians and managers \[[@pone.0238142.ref019]\]. Episodes of care can be searched based on the principal diagnosis. The principal diagnosis is defined as the diagnosis established to be chiefly responsible for occasioning the episode of care \[[@pone.0238142.ref018]\]. Episodes of care can be further described based on the length of stay and whether the episode was emergency or elective. Elective episodes of care are any scheduled hospital admission \[[@pone.0238142.ref018]\]. This includes scheduled attendances to the hospital for procedures such as bronchoscopies, and also scheduled admissions for inpatient hospital care. Emergency episodes of care are any unscheduled admission to a public hospital \[[@pone.0238142.ref018]\]. This includes unscheduled admissions to the hospital through an emergency department, medical assessment unit or unscheduled transfers between hospitals. Patients attending the outpatient department or the emergency department who do not get admitted to hospital are not captured by the HIPE system.

Comparative data on national TB case notifications were extracted from national TB surveillance reports for 2015--2018 \[[@pone.0238142.ref004],[@pone.0238142.ref020]--[@pone.0238142.ref022]\].

2.2 Data extraction {#sec008}
-------------------

The NQAIS Clinical was searched for all episodes of care where TB was the principal diagnosis and where discharge occurred between 01/01/2015 to 31/12/18. We extracted for every episode of care the patient identification number, age, sex, county of origin, postcode, admitting hospital, admission source, discharge destination, admission type (emergency or elective), principal speciality, length of stay, length of stay in intensive or coronary care, secondary diagnoses, readmission information and Charlson Comorbidity Index, The Charlson Comorbidity index is a method of quantifying morbidity and predicting mortality by classifying or weighting between 0 and 17 comorbid conditions \[[@pone.0238142.ref023]\]. Patients with an index of 0 are said to have none of the comorbidities contained in the Charlson Comorbidity Index, while for example, patients with moderate chronic kidney disease will have an index of 2.

2.3 Data analysis {#sec009}
-----------------

Across public hospitals in the ROI there is no unique patient identification number. This means the same patient can have one or multiple identification numbers within NQAIS Clinical if they have attended more than one hospital. We performed matching of episodes of care based on age, gender, county of residence, postal code, admission source, discharge destination and the patient identification numbers extracted from NQAIS Clinical to identify the number of patients in our cohort.

We searched data extracted to identify cases of respiratory TB and non-respiratory TB using the ICD-10 AM codes shown in [Table 1](#pone.0238142.t001){ref-type="table"} \[[@pone.0238142.ref024]\]. We also searched secondary diagnoses and place of residence for codes relating to homelessness, illicit drug use, imprisonment, diabetes mellitus, alcohol use or recent TB case contact. The European Centre for Disease Control (ECDC) advise that these variables, known as social determinants and risk factors (SDRFs) for TB, should be identified and monitored because they are thought to be important factors in the development of TB disease among people in Europe \[[@pone.0238142.ref025]\]. We searched the patients' records for secondary diagnoses which may inform potential reasons for hospital admission. These included sepsis, systemic inflammatory response syndrome, common side effects of antimycobacterial treatments, non-adherence to medication, isolation, and drug resistance.

10.1371/journal.pone.0238142.t001

###### Terms used to search NQAIS clinical.
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  Diagnosis                                                            ICD-10 Code/Term Used
  -------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Tuberculosis (all)                                                   A15.0--15.9, A16.0--16.9, A17.0, A17.1, A17.8, A17.9, A18-18.8, A19.0, A19.1, A19.2, A19.8, A19.9, B90.0, B90.1, B90.2, B90.8, B90.9, J65, M01.10--19, M49.0, M49.00--49.09, N33.0, N74.0, N74.1, P37.0, Z06.74, Z86.11
  Respiratory tuberculosis                                             A15.0--15.9, A16.0--16.9
  Diabetes                                                             E10.0--10.9, E11.0--119, E13.0--13.9, E14.0--14.9
  Homelessness                                                         Z59.0, admission source
  Illicit drug use                                                     Z72.2, F11.0--11.9, F14.0--14.9
  Alcohol misuse                                                       F10.0--10.9, K70.0-K70.9
  Being a prisoner                                                     Prison stated as admission source or discharge destination
  HIV                                                                  B20-24, Z21, R75, 098.7
  Contact with and exposure to tuberculosis                            Z20.1
  Sepsis or end-organ failure or volume depletion                      A41.0--41.9, R57.2, R65.0--0.3, R65.9
  J96.0, J96.1, J96.9, K72.0, K72.9, N17.9, F05.9, E86, I50.1, R41.0   
  Admission to intensive or coronary care coded                        
  Adverse effect of antimycobacterial drug                             Y41.1, Y40.6
  Rash, skin eruption                                                  R21, L27
  Nausea and vomiting, gastroenteritis and colitis                     R11, A09.9, K52.1,52.3, 52.8.52.9
  Abnormal liver function tests                                        R94.5
  Visual disturbance, optic neuritis                                   H53.0--3.9, H46
  Isolation                                                            Z29.0
  Resistance to antimycobacterial drug                                 Z06.6, Z06.7
  Non-adherence to medication                                          Z91.1

The cost of all TB inpatient episodes of care was estimated using costing guidance from the Healthcare Pricing Office \[[@pone.0238142.ref026]\]. We extracted the diagnosis-related grouping (DRG) for every episode of care coded on NQAIS Clinical as having TB as the principal diagnosis. DRGs are a means of classifying patient hospital encounters into a manageable number of groups which can be used to describe the mix of cases being managed by a hospital \[[@pone.0238142.ref026]\]. The DRGs group together cases which are clinically similar, and which are expected to consume a similar amount or resources. Each DRG can be further subdivided based on the level of complexity consumed during the admission into high, intermediate, and low complexity. Complexity refers to the intensity of the resource utilization rather than the clinical complexity. For example, a patient with a terminal illness being managed palliatively may be considered clinically complex but may have a low level of resource utilization and be referred to as low complexity. The cost of an episode of care was calculated using the DRGs, the level of complexity, the length of stay and the type of episode of care. Where the DRG complexity classification was missing from the data extracted from NQAIS Clinical we calculated the cost assuming first, the episode of care was of high complexity and then assuming it was of low complexity. This provides an upper and lower limit cost value for that episode of care.

Data analysis was performed using Microsoft Excel and Stata 16.0 (StataCorp. 2015). Using each patient's first emergency episode of care we performed logistic regression to compare differences in length of stay and cost between subgroups (patients with respiratory and non-respiratory TB, patients with and without SDRFs for TB, patients with a Charlson Comorbidity Index of zero and a Charlon Comorbidity Index of greater than zero). A chi-square test was performed to examine the relationship between categorical variables such as gender, disease site and the presence of SDRFs for TB. Ethical approval was received from the Royal College of Surgeons in Ireland Research Ethics Committee to perform this analysis of HIPE data and costing of episodes of care (reference number 1633).

3. Results {#sec010}
==========

3.1 Description of episodes of care {#sec011}
-----------------------------------

Between 2015 and 2018 there were 1185 episodes of care with TB as the principal diagnosis, 76.9% (911/1185) of which were in patients with respiratory TB ([Table 2](#pone.0238142.t002){ref-type="table"}). Emergency episodes of care made up 67.6% (801/1185) of all episodes of care, of which 76% (609/801) were in patients with respiratory TB. From 2015 to 2018 there were 1257 TB cases notified in the ROI. There were 818 patients identified after matching of episodes of care. We estimate that the proportion of TB cases notified who had an episode of care was 65.1% (818/1257). Of these, 73.1% (615/841) of cases of respiratory TB notified had an episode of care compared to 48.8% (203/416) of cases of non-respiratory TB. We estimate that 50.8% (639/1257) of cases notified had an emergency episode of care. Of these, 57.3% (482/841) of cases of respiratory TB notified had an emergency episode of care compared to 37.7% (157/416) of non-respiratory TB. Most of these patients had only one emergency episode of care (respiratory TB, 80.7% (389/482), non-respiratory TB 83.4% (131/157)).

10.1371/journal.pone.0238142.t002

###### Description of episodes of care.
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  ------------------------------------------------------------------------------ ------------- ---------------- --------------------
  Episodes of Care on NQAIS Clinical, 2015--2018                                                                
                                                                                 All           Respiratory TB   Non-respiratory TB
  Episodes of Care (proportion of all episodes of care)                          1185          911 (76.9%)      274 (23.1%)
  Emergency (proportion of all episodes of care)                                 801           609 (76.1%)      192 (23.9%)
  Elective (proportion of all episodes of care)                                  385           302 (78.4%)      83 (21.6%)
  Tuberculosis Cases Notified, Republic of Ireland, 2015--2018                                                  
                                                                                 All           Respiratory TB   Non-respiratory TB
  Cases (proportion of all cases notified)                                       1257          841 (66.9%)      416 (33.1%)
  Patients on NQAIS Clinical, 2015--2018                                                                        
                                                                                 All           Respiratory TB   Non-respiratory TB
  Patients (proportion of all cases notified)                                    818 (65.2%)   615 (73.1%)      203 (48.8%)
  Patients who had an emergency episode of care (proportion of cases notified)   639 (50.8%)   482 (57.3%)      157 (37.7%)
  Patients who had an elective episode of care (proportion of cases notified)    287 (23%)     220 (26.2%)      67 (16.1%)
  ------------------------------------------------------------------------------ ------------- ---------------- --------------------

60.7% (674/1108) of all episodes of care in adults aged 16 years and over occurred outside of the three hospitals deemed to be TB centres of care ([Table 3](#pone.0238142.t003){ref-type="table"}). 53% (589/1108) of episodes of care in patients aged 16 years and over were under specialists other than TB specialists.

10.1371/journal.pone.0238142.t003

###### Episodes of care by specialist and centre.
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                                                                             Episodes of Care   Emergency episodes of care (proportion of emergency episodes of care)   Elective episodes of care (proportion of elective episodes of care)
  -------------------------------------------------------------------------- ------------------ ----------------------------------------------------------------------- ---------------------------------------------------------------------
  Age 16 years and over                                                      1111               763                                                                     348
  TB Centre (in those age 16 years and over)                                 437 (39.3%)        258 (33.8%)                                                             179 (51.4%)
  Non-TB centre (in those age 16 years and over)                             674 (60.7%)        505 (66.2%)                                                             169 (48.6%)
  Principal speciality-TB specialist (in those aged 16 years and over)       522 (47%)          333 (43.6%)                                                             189 (54.3%)
  Principal speciality-Non-TB specialist (in those aged 16 years and over)   589 (53%)          430 (56.4%)                                                             159 (45.7%)

741/801 (80%) of emergency episodes of care had a Charlson Comorbidity Index of 0. 131/801 (16.4%) of emergency episodes of care had a side effect potentially attributable to anti-mycobacterial usage coded. 110/801 (13.7%) had a requirement for isolation of any type coded. 146/801 (18.2%) of emergency episodes of care had sepsis, systemic inflammatory response syndrome, volume depletion, end-organ dysfunction or a requirement for intensive care/coronary care coded. 21/801 (2.5%) had non-adherence to a medication coded. 18/801 (2.2%) had resistance to an antimycobacterial coded. 503/801 (61.5%) of episodes of care had none of these coded.

3.2 Patient characteristics {#sec012}
---------------------------

61% (499/818) of patients were male ([Table 4](#pone.0238142.t004){ref-type="table"}). This is similar to the proportion of males among TB cases notified (59.2% (744/1257)). The median age of patients was 43 years (interquartile range 23--60) and the age distribution of patients is similar to that of all TB cases notified over the same period ([Fig 1](#pone.0238142.g001){ref-type="fig"}). 75.2% (615/818) of patients had respiratory TB and 24.8% (203/818) of patients had non-respiratory TB. The proportion of patients with respiratory TB in our cohort is higher than that of the proportion of TB case notified (66.9% (841/1257)). The median ages of patients with respiratory and non-respiratory TB were equivalent (43 years (IQR 29--60) vs 43 years (IQR 29--61)). Males made up 62% (381/615) and 58.1% (118/203) of respiratory and non-respiratory TB patients, respectively.

![Age distribution of TB patients on NQAIS clinical and TB cases notified nationally.](pone.0238142.g001){#pone.0238142.g001}

10.1371/journal.pone.0238142.t004

###### Characteristics of patients with TB from NQAIS clinical and TB cases notified, Republic of Ireland, 2015--2018.
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  -------------------------------------------------------------- ---------------- ---------------- -------------------- ----------------------------------------------------
  Tuberculosis Cases Notified, Republic of Ireland, 2015--2018                                                          
                                                                 All              Respiratory TB   Non-respiratory TB   Comparison
  Total (proportion of all cases notified)                       1257             841 (66.9%)      416 (33.1%)          
  Male sex (proportion of all cases notified)                    744 (59.2%)      N/a              N/a                  
  Drug resistant TB                                              66/1257 (5.3%)   N/a              N/a                  
  Patients on NQAIS Clinical, 2015--2018                                                                                
                                                                 All              Respiratory TB   Non-respiratory TB   
  Total (proportion of all patients)                             818              615 (75.2%)      203 (24.8%)          
  Median age (interquartile range)                               43 (23--60)      43 (29--60)      43 (29--61)          
  Male sex (proportion of total)                                 499 (61%)        381 (62%)        118 (58.1%)          
  Drug resistant TB                                              14/818 (1.7%)    13 (2.1%)        1 (\<1%)             
  HIV (proportion of total)                                      28 (3.4%)        21 (3.4%)        7 (3.4%)             
  Any SDRF for TB (proportion of total)                          138 (16.9%)      115 (18.7%)      23 (11.3%)           Respiratory TB versus non-respiratory TB P = 0.02
  Diabetes (proportion of total)                                 60 (7.3%)        44 (7.2%))       16 (7.9%)            
  Alcohol misuse (proportion of total)                           53 (6.5%)        49 (8%)          4 (2%)               Respiratory TB versus non-respiratory TB p = 0.002
  Illicit drug use (proportion of total)                         18 (2.2%)        17 (2.3%)        1 (\<1%)             
  Incarceration (proportion of total)                            3 (\<1%)         2 (\<1%)         1 (\<1%)             
  Contact with and exposure to TB (proportion of total)          10 (1.2%)        10 (1.6%)        0                    
  Homelessness (proportion of total)                             15 (2.2%)        14 (2.3%)        1 (\<1%)             
  Died during an episode of care (proportion of total)           18 (1.7%)        13 (2.1%)        5 (2.4%)             
  -------------------------------------------------------------- ---------------- ---------------- -------------------- ----------------------------------------------------

N/a = Not available.

16.9% (138/818) of patients had a SDRF for TB. The median age of patients with SDRF for TB was greater than that of patients without SDRF for TB (51 years (43--63) vs 40 years (IQR 28--59), P \< .001, S1 Table in [S1 File](#pone.0238142.s001){ref-type="supplementary-material"}). Males made up a higher proportion of patients with SDRF for TB compared those without SDRFs for TB (79% (109/138) vs. 57.4% (390/680)). The relation between gender and having SDRFs for TB was significant, (χ^2^ (1, N = 138) = 22.57, P \< .001, S1 Table in [S1 File](#pone.0238142.s001){ref-type="supplementary-material"}). A higher proportion of respiratory TB patients had a SDRF for TB compared to non-respiratory TB patients (18.7% (115/615) vs 11.3% (23/203)) and this relation was significant (χ^2^ (1, N = 818) = 5.9098, P = .02, [Table 4](#pone.0238142.t004){ref-type="table"}). This was mainly due to a higher proportion of alcohol misuse in those with respiratory TB (8% (49/615) vs 2% (4/203), P = .002, [Table 4](#pone.0238142.t004){ref-type="table"}). The most prevalent SDRFs for TB were diabetes, 7.3% (60/818), and alcohol misuse, 6.5% (53/818).

3.3 Cost of episodes of care with a principal diagnosis of TB {#sec013}
-------------------------------------------------------------

In total 16,005 bed-days were utilised across 38 hospitals by patients with a principal diagnosis of TB, of which 87.9% (14060.5/16005) were during an emergency episode of care. The cost of all episodes of care was €10,555,312--11,820,186, of which 85.3--86.5% (€9,003,702--10,229,587) was attributable to emergency episodes of care. The estimated average cost of TB hospital care per year in the ROI from 2015 to 2018 was €2,638,828--2,955,047, with emergency episodes of care costing an average of €2,250,926--2,557,397 per year.

11769.5/16005 (73.5%) of bed-days were utilized by patients with respiratory TB. Patients with a higher cost of emergency episodes of care per thousand euro were less likely to have respiratory TB than non-respiratory TB (odds ratio (OR) 0.978, 95% CI 0.966--0.991, P = .001, S3 Table in [S1 File](#pone.0238142.s001){ref-type="supplementary-material"}). Patients with non-respiratory TB had a higher cost per bed-day than patients with respiratory TB (€837--854 vs. €571--683, [Table 5](#pone.0238142.t005){ref-type="table"}). There was no association between the length of stay and whether the patient had respiratory TB or non-respiratory TB (OR 0.994, 95% CI 0.987--1.001, P = .111, S3 Table in [S1 File](#pone.0238142.s001){ref-type="supplementary-material"}).

10.1371/journal.pone.0238142.t005

###### Cost of episodes of care in respiratory and non-respiratory TB patients.
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                                               Respiratory TB             Non-respiratory TB                                                                                          
  -------------------------------------------- -------------------------- -------------------------- -------------------------- -------------------------- -------------------------- --------------------------
  Total (proportion of all episodes of care)   609 (67.1%)                299 (32.9%)                908                        192 (69.3%)                85 (30.7%)                 277
  Number of patients                           482                        220                        615                        157                        67                         203
  Number of bed-days 2015--2018                10387                      1382.5                     11769.5                    3673.5                     562                        4235.5
  Median length of stay (days) (IQR)           9 (5--19)                  0.5 (0.5--2)               6 (0.5--15)                12.5 (6--21)               0.5 (0.5--7)               8 (2--18)
                                               Cost (lower-upper limit)   Cost (lower-upper limit)   Cost (lower-upper limit)   Cost (lower-upper limit)   Cost (lower-upper limit)   Cost (lower-upper limit)
  Total cost (€)                               5,927,708--7,090,711       1,091,440--1,131,536       7,019,148--8,222,247       3,075,934--3,138,876       459,062--460,169           3,536,103--3,597,938
  Mean cost per year (€)                       1,481,927--1,772,678       272,860--282,884           1,754,787--2,055,562       768,984--784,719           114,765--115,042           884,023--899,485
  Mean cost per episode (€)                    9,734--11,643              3,650--3,784               1,933--2,264               16,021--16,348             5,401--5,414               3,191--3,247
  Mean cost per case notified (€)              7,048--8,431               1,298--1,345               8,346--9,777               7,394--7,545               1,104--1,106               8,500--8,649
  Mean cost per bed-day (€)                    571--683                   789--818                   596--699                   837--854                   817--819                   835--849

Patients with a longer length of stay for emergency episodes of care were more likely to have SDRFs for TB (OR 1.017, 95% CI 1.009--1.025, P\<0.001, S4 Table in [S1 File](#pone.0238142.s001){ref-type="supplementary-material"}) and were more likely to have a Charlson Comorbidity Index greater than zero (OR 1.024, 95% CI 1.015--1.033, P \< .001, S5 Table in [S1 File](#pone.0238142.s001){ref-type="supplementary-material"}). Patients with a higher cost of emergency episodes of care per thousand euro were also more likely to have SDRFs for TB (OR 1.01, 95% CI 1.001--1.019, P = -.034, S4 Table in [S1 File](#pone.0238142.s001){ref-type="supplementary-material"}) and were more likely to have a Charlson Comorbidity Index of greater than zero (OR 1.045 95% CI 1.028--1.062, P \< .001 S5 Table in [S1 File](#pone.0238142.s001){ref-type="supplementary-material"}).

When comparing patients with drug resistant and drug sensitive TB there was no difference in the cost of emergency episodes of care per thousand euro (OR 1.009, 95% CI .994--1.023, P = .233, S6 Table in [S1 File](#pone.0238142.s001){ref-type="supplementary-material"}) but the length of stay was greater in those with drug resistant TB (OR 1.016, 95% CI 1.004--1.027, P = 0.004, S6 Table in [S1 File](#pone.0238142.s001){ref-type="supplementary-material"}).

4. Discussion {#sec014}
=============

Our study shows there is a high need for inpatient care among patients with TB in the ROI. A higher proportion of patients with respiratory TB appear to require unscheduled emergency inpatient care than patients with non-respiratory TB. Patients with non-respiratory TB had more costly emergency episodes of care. We demonstrated that patients with longer and more costly emergency episodes of care were more likely to have SDRFs for TB and to have comorbidity (as measured by the Charlson Comorbidity Index). Whether this is related to more clinically complex episodes of care or the need for enhanced support to enable timely discharge is unclear from our data. We found that most episodes of care occurred outside of TB centres and not under the direct care of a TB specialist. This pattern of care is at variance with our national guidelines and policy \[[@pone.0238142.ref009],[@pone.0238142.ref016]\]. The annual cost of emergency episodes of care in patients with TB was high (€2.25m-2.57m) considering the incidence of TB in the ROI is low. From our cohort, we found most emergency episodes of care did not have a common antimycobacterial side effect, non-adherence or drug resistance coded as a secondary diagnosis. This suggests that emergency episodes of care were not related to these factors in most cases. The proportion of patients coded as having sepsis, end-organ dysfunction or a need for intensive/coronary care was also low, suggesting patients presenting with critical illness was not a significant factor either.

A dependence on hospital inpatient services in the management of TB patients and the associated high costs is not unique to the ROI. TB services in other low-incidence countries have described similar experiences. In Germany, a reduction in the overall cost of TB disease to the state was attributed to a reduction in the proportion of TB patients requiring inpatient care from 80% to 71.2% over 5 years \[[@pone.0238142.ref027]\]. A 2010 study in New York City found that 72% of their cohort required hospital admission, many of which could have been avoided \[[@pone.0238142.ref028]\]. A national survey in Italy found that 71.6% of all TB cases were hospitalised \[[@pone.0238142.ref029]\].

It is difficult to ascertain what value is derived from such a high and costly utility of unscheduled emergency care given that treatment outcomes are unknown for a large proportion of TB cases in the ROI \[[@pone.0238142.ref030]\]. In 1959 a significant study in TB care demonstrated that patients with TB could be treated at home with similar outcomes to treatment in hospitals \[[@pone.0238142.ref031]\]. Many tuberculosis programs have since aimed to provide care without the need for prolonged hospitalisation \[[@pone.0238142.ref028],[@pone.0238142.ref029]\]. The high cost of inpatient care in the ROI and the potential for TB disease transmission in institutional settings should act as an impetus to minimizing the hospitalization of patients with TB unnecessarily. Research examining the needs of TB patients seeking emergency care should be performed and outpatient services should be optimized to meet these needs where possible.

The WHO guidance on Directly Observed Treatment (DOTs) states that a key component of a DOTs program is a standardized recording and reporting system that allows assessment of treatment results for each patient and of the TB control programme overall \[[@pone.0238142.ref032]\]. We propose establishing a regular national cohort review of all TB cases in the ROI to ensure there is a process of quality improvement, improved reporting of TB outcomes and specialist involvement in care provided to all patients. Cohort review has been beneficial to case management elsewhere, such as in the United Kingdom \[[@pone.0238142.ref033]\]. In parallel with this, we propose a national TB leader, with regional coordinators supported by a national multi-disciplinary team (MDT), including public health specialists, community and primary care doctors and nurses, those treating latent TB, diagnostic laboratory staff, scientists working on tuberculosis control and the service managers. A national TB lead and MDT would follow the WHO DOTs guidance, which states that governments should demonstrate a commitment to sustained TB control activities \[[@pone.0238142.ref032]\]. While the last policy on TB services in Ireland recommended three tertiary referral hospitals as TB centres, our study shows that TB patients present to many hospitals and are managed under many specialities. This suggests that a model of TB governance in Ireland not geographically restricted to three sites is needed.

There may be a need to provide dedicated funding to outpatient TB services in the ROI. Public hospitals in the ROI are funded based on activities performed as opposed to treatment outcomes \[[@pone.0238142.ref026]\]. Healthcare funding models based on activities performed have resulted in an over-dependence on inpatient TB care in other settings \[[@pone.0238142.ref034]\]. Addressing funding mechanisms for TB care is important in addressing this. Linking the funding received by TB centres for outpatient services to treatment outcomes for TB patients in their region may have a role in reducing the number of episodes of care in hospitals. This would likely be less expensive for the health service \[[@pone.0238142.ref027],[@pone.0238142.ref034]\].

A strength of this study is that it captures data on TB admissions from all acute public hospitals in the ROI across 4 years. This study had several limitations. An audit of coding standards in the ROI found that HIPE data lacked specificity compared to international standards, which may lead to under-reporting of clinical complexity \[[@pone.0238142.ref035]\]. The primary reason for this was difficulty in extracting information from poorly structured medical records. Therefore, there may be an under-representation of TB complexity and cost within the HIPE dataset. This may be improved on with the national roll-out of an electronic health record making information easier to interpret and code \[[@pone.0238142.ref036]\]. There is no unique patient identifier across all public hospitals in the ROI. We performed a rigorous matching process based on age, gender, county of residence and postal code. There is a possibility this process matched episodes of care by two different patients to one patient, resulting in an underestimation of the number of patients. There is an ongoing process to implement a unique patient identifier across all hospital in the ROI which when fully implemented would overcome this limitation in any future evaluations \[[@pone.0238142.ref037]\]. This study was limited by the absence of data on TB patients managed in private hospitals in the ROI, which are not captured by the HIPE system. It does not capture presentations to hospital emergency departments which do not result in hospital admission. The patient's country of birth is also not captured which is relevant when discussing TB in low-incidence countries. A significant limitation is that it was not possible to crossmatch cases notified nationally with admissions coded in HIPE data, meaning we could only provide estimates of the proportion requiring admission.

5. Conclusion {#sec015}
=============

There is a significant burden on the acute hospital inpatient service from tuberculosis in the Republic of Ireland. The national TB policy should change in recognition of this.
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Thank you for reviewing our manuscript and providing constructive comments. We present a considerably improved version of our original manuscript which hopefully you find acceptable. Our response to reviewers' comments are outlined below.

Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.
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We have uploaded a Microsoft Excel file which contains the data underlying our results. We have included additional tables which describe the data underlying our results. We hope this demonstrates that the results are based on technically sound analysis and interpretation of the data. While the original manuscript costed only respiratory TB episodes of care we now include the costing of all TB episodes of care using the same methodology. The data underlying the costing is available in the supplementary excel file.

Reviewer 1

Some explanatory text or background information that puts the TB program of Ireland into context is necessary

We have included a detailed description of the health system in the Republic of Ireland in the introduction section and also explained how the TB service is arranged in this context.

It is assumed that patients are diagnosed in the community and then sent to the hospital for admission/connection to TB care.

We agree that ideally the patient would be diagnosed in primary care and referred to the TB clinic for management however there is little data collected nationally to support or refute this assumption. An unpublished clinical audit from our own tertiary referral centre found over an 18 month period 16/40 patient diagnosed with TB first presented with their symptoms directly to the Emergency Department, 18/40 were attending their primary care physician of which 5/18 were sent by their primary care physician to the emergency department. These figures, in our region at least, would refute the assumption that the majority of TB is diagnosed in primary care. It is not possible to ascertain the reason for an episode of care from the national coding data outside of what the principal diagnosis was.

Would these be \"unscheduled\" admissions?

We have elaborated in the methods section what is mean by our use of the term "unscheduled". If the patient attends the Emergency Department, either with or without a referral by their primary care doctor then this is "unscheduled". Scheduled or planned hospital admissions such as those for procedures e.g. a bronchoscopy are referred to as "elective". We have standardised our usage of terminology throughout the manuscript using the terms "emergency", "elective" and "episode of care" and defined these terms in the methods section.

Most hospital admissions were emergency admissions and emergency rooms are notoriously bad at diagnosing TB.

Patients who have an episode of care coded are those who attended the emergency department and were admitted to hospital. They are seen by an emergency department doctor and referred to the internal hospital doctor for hospital admission if it is agreed it is necessary. The data recorded and reported on in this study does not describe patients who were seen by an emergency department doctor and not referred for admission. This as you have rightly pointed out that patients with undiagnosed TB could present to an emergency department and not have their diagnosis established. As such, data reported in this study more than likely is an under representation of patients with TB seeking care by attending a hospital emergency department.

What is the role of the public health department - who oversees the program?

We have included a description of the role of public health departments in TB care. They largely are not involved in the assessment of people with signs and symptoms of TB outside of contact tracing of known cases. While in other countries TB clinics can have strong involvement of public health departments, in the Republic of Ireland clinics are typically operated by infectious diseases and respiratory physicians in tertiary care centres. We have commented on this in the introduction section.

How are patients that are not sent to the hospital processed?

Typically, patients will be referred to an outpatient clinic operated by a specialist with expertise in TB, usually but not necessarily one of the 3 TB services operating in the country. We have commented on this in the introduction section

Who is responsible for post-hospital care? How are in-hospital and out-of-hospital care connected.

Post-hospital care is the responsibility of the primary are doctor unless the patient has been referred to an outpatient service on discharge from the hospital. We have tried to describe the health system and TB service in Ireland throughout the introduction and methods section using the questions posted by reviewer 1 as guidance in the introduction section.

Most emergency admissions had a principal diagnosis of respiratory TB (74.%) - from a public health - infection control/occupational health and safety - perspective it would be very important for the emergency room/hospital to know in advance whether these patients were coming. Were proper precautions taken/did all the model facilities have respiratory isolation capacity - did this influence the designation of three TB centres in 2003?

All hospitals seeing acute medical patients in Ireland would have at least 1 negative pressure isolation room. Whether this was available or utilized appropriately for patients admitted with TB can not be deduced from our hospital coding data. We searched for a requirement for isolation in the secondary diagnoses and found it was not coded often, which could suggest it was either not required or it was not used appropriately or there is under reporting of its use within the coding data. The designation of the three TB centres in 2003 was based on the regional incidence of TB, the geographic location of the hospitals, their role as tertiary referral centres within the regions and the existing expertise in TB care within these hospitals.

The results section could be a little clearer - a lot of information is presented and it relates to individuals and admissions; with one individual having the potential for multiple admissions.

We have heavily refined our results section. It now includes a costing of all TB episodes of care. We present first a description of the episodes of care found from our search and then a description of the patient characteristics. Overall we think it is clearer to the reader.

it would be helpful if the authors created at least one additional TABLE and two or three FIGUREs. The TABLE might contain information on the age, sex, country of birth (Ireland vs Foreign-born) and disease site (respiratory and non-respiratory) of (i) their notified cases and (ii) the unique cases in their admissions dataset.

We have included one table which describes the patient cohort as suggested. Unfortunately, data on country of birth is not available from our hospital coding data so this important comparison could not be made.

The FIGUREs might contain a breakout of their 735 emergency admissions according to the results provided in sections 3.1-3.3. Most of the text refers to the 735 emergency admissions; but in places (line 162 and the FIGURE) the authors include the 67 patients who were same-day admissions/discharges.

In our original manuscript we made a distinction between 735 emergency admissions which had a length of stay \>/= 1 day and 67 admissions which were discharged on the same day as admission. For simplicity we have removed this distinction from the manuscript by referring to all of these admissions together as "emergency episodes of care". We have included a table which shows the breakdown of admissions.

The authors need to clarify how they managed the admission if TB itself was the secondary diagnosis.

The aim of our study was to determine the utilization of hospital care due to tuberculosis. In our coding data the principal diagnosis is the diagnosis which resulted in the patient requiring hospitalization. Had we searched the secondary diagnoses of all patients we would have found additional episodes of care in patients who currently have TB or had TB at an unknown point in the past. These admissions would not have been due to TB and whether the diagnosis of TB is current or historical would not have been possible to determine. For these reasons searching the principal diagnoses provides the most accurate cohort of patients to represent hospital care utilization due to TB.

Did the authors have access to information about the HIV/AIDS status of their patients and the drug-resistance patterns in the isolates from those that were culture positive; these variables would almost certainly have an influence on length of stay, model of hospital and the type of physician caring for the patient.

Yes, we have included the proportion of patients with HIV and drug resistance coded, both were quite low. It may be the case that these results were not available at the time of discharge from hospital when coding of the patients record took place. We demonstrated that patients with drug resistance had more costly episodes of care.

The Charlson score should be defined for readers who may not be familiar with it.

We have defined the Charlson Score for readers.

Reviewer \#2: This is an interesting manuscript on a topic of local importance. However, I have some serious concerns about data that are missing from this analysis, without which the conclusions and policy recommendations will be deeply flawed.

My main concerns are with the following 2 points: First, the authors do not separate out or address in their discussion the fact that they found significant increases in hospitalizations and duration of hospitalization in people with social determinants of TB, which include homelessness, incarceration, alcohol use disorders, among others. In many places, these patients end up admitted and staying longer because of these factors. This may be very important for the costing considerations\--would someone homeless or incarcerated be able to be discharged \"home\" as rapidly as those who are not? Patients with alcohol use disorders are also often kept longer or followed more closely to ensure that they do not have dangerous side effects. And often, these social determinants keep people from presenting with symptoms earlier, before the situation becomes an emergency.

We have acknowledged the higher cost and longer length of stay in patients with social determinants and risk factors for TB. We agree the issue may be one or a combination of delayed presentation, delayed discharge due to a lack of a suitable destination and more clinically complex inpatient episodes of care. It was not possible for us to determine from coded data which of these hypotheses explains our finding. We have acknowledged this in the discussion

Second, a huge limitation for me with this paper is that there is no differentiation made between people with drug sensitive and drug-resistant disease. I don;t know what the policies are in Ireland, but in many countries, MDR patients require hospitalization for several weeks. Without knowing the reality of these situations, policy recommendations (such as \"Reductions in the number of hospital

admissions of TB patients in Ireland should be pursued\" line 236) may be misguided.

We found the proportion of patients with drug resistance coded was low in our cohort (1.7% of all patients compared to 5.3% of cases notified). We agree that patients with typically require MDR-TB prolonged inpatient care. From 2015- 2018 in Ireland there were 17 cases of MDR-TB notified. The vast majority of patients have pan sensitive (94.7%) or monoresistant TB (3.9%), as such we have not focused our policy interventions on MDR-TB. It is also likely they are under-represented within the coding data. This may be due to the unavailability of TB culture results at the time of discharge from hospital.

Lines 110-113: the authors seem to define emergency admissions twice\--once with same day stay and once with overnight stay. Could it be clarified that these are different endpoints and will both be considered?

In our original manuscript we made a distinction between 735 emergency admissions which had a length of stay \>/= 1 day and 67 admissions which were discharged on the same day as admission. For simplicity we have removed this distinction from the manuscript by referring to all of these admissions together as "emergency episodes of care".

Line 121: please define charlson score for non-clinician readers, & give some info about how it\'s used. What\'s a possible range of scores? What does a score of 0 imply or mean vs. a score of 20?

We have defined the Charlson Score for readers and provided an example.

Lines 118-131\--the authors talk about their analysis methods but it\'s not clear what they are comparing with the chi2 tests.

We have elaborated on our description of our statistical analysis to describe what we associations and comparison we are making.

Line 136 definition of \"complexity\" is quite vague. What does it mean to have resource complexity? An example here would help.

We have elaborated that complexity refers to the resources consumed during an episode of care as opposed to the clinical complexity of a case. We have included an example

Line 142: Is this ethics review for the whole study, or just the costing piece? If whole study, put this in a separate paragraph. Also, the ID number of the Ethics committee would be great to include if you have it.

The ethics review approved all components of the study. I cannot find an ID number for the ethics committee, I have inserted the reference number for my ethics application to that committee.

Lines 158 to 160: are the number of bed-days distributed Gaussian or are the data skewed? If skewed, which I suspect is sort of usual for TB stay durations, I\'d suggest presenting the median and IQR instead of the mean. Or present both. mean bed-days as a descriptive measure could be deceptive if you have a few very long stays and most quite short.

The data is skewed. We agree and we have now presented the median and interquartile range.

I hope I have addressed your concerns above and look forward to hearing your decision.
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Please include the following items when submitting your revised manuscript:
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: (No Response)

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: There were unfortunate limitations to the datasets used by the authors. It is suggested that, in the Discussion, they mention this limitation and that efforts be made to address it, so that in the future they can track, yet more completely, the effect of their reforms.

Reviewer \#2: I appreciate the opportunity to re-review this manuscript and appreciate the authors\' attention to and responses to my earlier comments. I believe the revisions to be complete. I have a few additional comments about the revision.

1\) although in the text, the authors present evidence of statistical significance through the use of p-values, these are not presented in the tables at all. I strongly suggest that they be presented in a column in the tables; standard practice, as far as I know.

2\) One of the assumptions of the Mann-Whitney U test is independence of observations. If you have 800 or so people but 1180 episodes of care, at least some of those are going to be on the same individuals, and thus may violate this assumption. You may want to include a sentence in your limitations section about that.

3)line 229: unbalanced number of parentheses

4)Table 2, respiratory TB/Elective box unbalanced parentheses

5\) line 263 and beyond\--ensure you are using a \"chi\" symbol, and not an \"X\"

6\) Table 6, no SDRFs columns are missing some percentages

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Dear Editor and Reviewers,

Thank you for once more taking the time to review our submission and providing rigorous feedback. Our responses to the comments are outlined below. We hope the changes submitted are sufficient to meet the standard of publication.

1\. "There were unfortunate limitations to the datasets used by the authors. It is suggested that, in the Discussion, they mention this limitation and that efforts be made to address it, so that in the future they can track, yet more completely, the effect of their reforms."

Yes, we agree this is the prime limitation in the research method. We have included a comment which highlights this limitation. We feel that our matching process based on age, gender, county of residence and postal code could potentially match episodes of care to the same patient when in fact they may have been due to different patients. This means the number of patients in the dataset is, if anything, an underestimation meaning the problem highlighted of a high proportion of cases notified requiring hospitalization may even be higher than estimated in this paper. We highlight an already ongoing project in the Republic of Ireland to provide a unique patient identifier across all public hospitals which would overcome this problem when evaluating the service in the future.

The second notable limitation is that the hospital coding data collection process in the ROI is imperfect and lacks specificity i.e. when the coder was uncertain of how to code an episode of care they allocate it to a non-specific ICD-10 code and they may allocate a diagnosis related grouping of lower complexity and therefore lower cost. We cite a national audit which found the primary reason for these discrepancies is that coders were unable to find the relevant information in poorly maintained hospital paper records. We highlight an ongoing national project to rollout an electronic health record to all public hospitals.

2\. "although in the text, the authors present evidence of statistical significance through the use of p-values, these are not presented in the tables at all. I strongly suggest that they be presented in a column in the tables; standard practice, as far as I know"

We have included a column labelled "comparison" which includes the comparison made and the associated p-value. In the supplementary file a column for P values is also included in each table.

3\. "One of the assumptions of the Mann-Whitney U test is independence of observations. If you have 800 or so people but 1180 episodes of care, at least some of those are going to be on the same individuals, and thus may violate this assumption. You may want to include a sentence in your limitations section about that"

We agree with this statement. We have re-analysed our data. We have performed logistics regression instead of a Mann-Whitney U test to compare length of stay and cost of episodes of care between patients with respiratory and non-respiratory TB, patients with SDRFs for TB and those without SDRFs for TB and those with comorbidity and those without comorbidity (as measured by the Charlson Comorbidity Index). We have performed this analysis for all patients first episode of care to ensure there is independence in the observations analysed. We have included the results of these analyses, including p-values, in the supplementary file.

4."line 229: unbalanced number of parentheses"

We have corrected this.

5."Table 2, respiratory TB/Elective box unbalanced parentheses"

We have corrected this.

6."line 263 and beyond\--ensure you are using a \"chi\" symbol, and not an \"X\""

We have corrected this.

7."Table 6, no SDRFs columns are missing some percentages"

We have corrected this.
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Dear Dr. O Connell,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Wen-Jun Tu

Academic Editor

PLOS ONE
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Dear Dr. O\'Connell:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Wen-Jun Tu

Academic Editor

PLOS ONE
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